1. Home
  2. NMS vs QNTM Comparison

NMS vs QNTM Comparison

Compare NMS & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMS
  • QNTM
  • Stock Information
  • Founded
  • NMS 1993
  • QNTM 1998
  • Country
  • NMS United States
  • QNTM Canada
  • Employees
  • NMS N/A
  • QNTM N/A
  • Industry
  • NMS Finance Companies
  • QNTM
  • Sector
  • NMS Finance
  • QNTM
  • Exchange
  • NMS Nasdaq
  • QNTM NYSE
  • Market Cap
  • NMS 66.4M
  • QNTM 69.3M
  • IPO Year
  • NMS N/A
  • QNTM N/A
  • Fundamental
  • Price
  • NMS $11.37
  • QNTM $18.56
  • Analyst Decision
  • NMS
  • QNTM
  • Analyst Count
  • NMS 0
  • QNTM 0
  • Target Price
  • NMS N/A
  • QNTM N/A
  • AVG Volume (30 Days)
  • NMS 12.0K
  • QNTM 408.2K
  • Earning Date
  • NMS 01-01-0001
  • QNTM 08-13-2025
  • Dividend Yield
  • NMS 4.11%
  • QNTM N/A
  • EPS Growth
  • NMS N/A
  • QNTM N/A
  • EPS
  • NMS N/A
  • QNTM N/A
  • Revenue
  • NMS N/A
  • QNTM N/A
  • Revenue This Year
  • NMS N/A
  • QNTM N/A
  • Revenue Next Year
  • NMS N/A
  • QNTM N/A
  • P/E Ratio
  • NMS N/A
  • QNTM N/A
  • Revenue Growth
  • NMS N/A
  • QNTM N/A
  • 52 Week Low
  • NMS $9.21
  • QNTM $2.70
  • 52 Week High
  • NMS $12.18
  • QNTM $38.25
  • Technical
  • Relative Strength Index (RSI)
  • NMS 44.41
  • QNTM 50.64
  • Support Level
  • NMS $11.30
  • QNTM $15.88
  • Resistance Level
  • NMS $11.45
  • QNTM $24.32
  • Average True Range (ATR)
  • NMS 0.08
  • QNTM 3.58
  • MACD
  • NMS 0.01
  • QNTM -1.07
  • Stochastic Oscillator
  • NMS 55.56
  • QNTM 13.59

About NMS Nuveen Minnesota Quality Municipal Income Fund

Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Share on Social Networks: